Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Ultragenyx Pharmaceutical is facing challenges, particularly reflected in its EPS miss. The stock dropped 6.34% in reaction to the lack of revenue details and guidance, signaling investor concern about the company's future performance and strategy.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.19 | N/A | -24.43% |
| Revenue | N/A | N/A | N/A |
Overall, management's tone was cautious, reflecting uncertainty about upcoming performance. They did not provide detailed insights into revenue or future expectations.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges but did not elaborate on future strategies.